Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
In the last three months, 7 analysts have published ratings on Emergent BioSolutions (NYSE:EBS), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 7 | 0 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 0 | 0 |
2M Ago | 5 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Emergent BioSolutions and provided 12-month price targets. The average target is $8.0, accompanied by a high estimate of $8.00 and a low estimate of $8.00. This upward trend is evident, with the current average reflecting a 5.68% increase from the previous average price target of $7.57.
A comprehensive examination of how financial experts perceive Emergent BioSolutions is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Robert Wasserman | Benchmark | Maintains | Buy | $8.00 | $8.00 |
Robert Wasserman | Benchmark | Maintains | Buy | $8.00 | $8.00 |
Robert Wasserman | Benchmark | Maintains | Buy | $8.00 | $8.00 |
Robert Wasserman | Benchmark | Maintains | Buy | $8.00 | $8.00 |
Robert Wasserman | Benchmark | Maintains | Buy | $8.00 | $8.00 |
Robert Wasserman | Benchmark | Maintains | Buy | $8.00 | $8.00 |
Robert Wasserman | Benchmark | Raises | Buy | $8.00 | $5.00 |
For valuable insights into Emergent BioSolutions's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Emergent BioSolutions analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3 months period, Emergent BioSolutions faced challenges, resulting in a decline of approximately -25.11% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Emergent BioSolutions's net margin excels beyond industry benchmarks, reaching -114.11%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Emergent BioSolutions's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -53.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Emergent BioSolutions's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -17.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Emergent BioSolutions's debt-to-equity ratio stands notably higher than the industry average, reaching 2.23. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: EBS